Chronic obstructive pulmonary disease medical therapy

Chronic obstructive pulmonary disease Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Chronic obstructive pulmonary disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
Echocardiography or Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
Case Studies
Case #1
Chronic obstructive pulmonary disease medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Chronic obstructive pulmonary disease medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Chronic obstructive pulmonary disease medical therapy
CDC on Chronic obstructive pulmonary disease medical therapy
Chronic obstructive pulmonary disease medical therapy in the news
Blogs on Chronic obstructive pulmonary disease medical therapy
Directions to Hospitals Treating Chronic obstructive pulmonary disease
Risk calculators and risk factors for Chronic obstructive pulmonary disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Philip Marcus, M.D., M.P.H. [2]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [3]

Overview

Treatment of COPD requires a careful and thorough evaluation by a physician. The most important aspect of treatment is avoiding tobacco smoke and removing other air pollutants from the patient’s home or workplace. Symptoms such as coughing or wheezing can be treated with medication. Respiratory infections should be treated with antibiotics, if appropriate. Patients who have low blood oxygen levels in their blood are often given supplemental oxygen. Currently, no treatment has been found to be totally curative against COPD except lung transplant. The treatments aim to improve lung function and quality of life.

Goal of treatment

• Improve a patient's functional capacity
• Improve symptoms
• Reduce exacerbation
• Improve quality of life

General therapy

• Patient education session about the disease, a self-treatment plan for exacerbations, and a monthly follow-up call from hospital or nurse practitioner , is associated with a lower hospitalization rate and fewer emergency department visits ,
• Treatment of COPD requires a careful and thorough evaluation by a physician.
• The most important aspect of treatment is avoiding tobacco smoke and removing other air pollutants from the patient’s home or workplace.
• Patients who have low blood oxygen levels in their blood are often given supplemental oxygen.
• Oral and inhaled medications are used for patients with stable chronic obstructive pulmonary disease (COPD) to reduce dyspnea, improve exercise tolerance, and prevent complications. Symptoms such as coughing or wheezing can be treated with bronchodilators like subcutaneous medications, beta-adrenergics, methylxanthines, and anticholinergics. They act via decreasing muscle tone in small and large airways in the lungs.
• Respiratory infections should be treated with antibiotics, if appropriate.

Beta adrenergic receptor agonists

Short acting selective B2 agonist

• Used for symptomatic relief during acute mild, exacerbation
• Mechanism of action - Increases intracellular cyclic adenosine monophosphate via activation of B2 -adrenergic receptors on smooth muscle cells of airway and causes smooth muscle relaxation.
• These agents are less effective in COPD compared to Asthma.
• Drugs available are:

Albuterol, Metaproterenol, Pirbuterol

• Used for bronchospasm refractory to epinephrine.
• Route - Inhaled

Levalbuterol

• Albuterol is a racemic mixture containing both R and S enantiomer. The S enantiomer doesn't bind to Beta 2 receptor and maybe the cause of side-effects. On the other hand, levalbuterol has only active R enantiomer thus causes less side-effects.
• It is used for both treatment and prevention of bronchospasm.

Long acting beta-2 adrenergic receptor agonist

• The long acting beta 2 receptor agonist are used to alleviate chronic persistent symptoms
• They help to increase exercise tolerance, prevent nocturnal dyspnea, and improve quality of life.
• Long-acting beta-agonists include salmeterol, formoterol, arformoterol, and indacaterol.
• They all require twice-daily dosing, except for indacaterol. Bronchodilating effect lasts more than 12 hours. Indacaterol is administered once daily.

Salmeterol, Formoterol, Arformoterol

• Relieve bronchospasms.

• Facilitate expectoration, improve symptoms and morning peak flows.

• Used in addition to anticholinergic agents.

Arformoterol

• Higher potency than racemic formoterol.

Indacaterol

• Indacaterol a long-acting beta2-agonist (LABA) is used for long-term, once-daily maintenance in patients with chronic obstructive pulmonary disease (COPD) .
• It is not for use as initial therapy in patients with acute deteriorating COPD.

Anticholinergics

• Anticholinergic drugs act as a competitive inhibitor of acetylcholine and block their action on postganglionic muscarinic receptors, thus inhibiting cholinergically mediated bronchspasm and resulting in bronchodilatation.

• They block vagally mediated reflex arcs that cause bronchoconstriction.

• Reported adverse effects include dry mouth, metallic taste, and prostatic symptoms.

Ipratropium

• They have similar efficacy as beta 2 adrenergic receptor agonist.
• They have a synergistic effect on broncho-dilatation when combined with beta 2 agonist.
• They have a slower onset and longer duration of action. Thus, lesser helpful in use on an as-needed basis.
• Dose - 2-4 puffs at 6-8 hour duration.

Tiotropium

• It is the only long-acting muscarinic (once daily) anti-cholinergic agent available at this time
• It has become a first-line therapy in patients with persistent symptoms.
• It is more effective than salmeterol in preventing exacerbation

Xanthine derivatives

Theophylline

• Causes inhibition of enzyme phosphodiesterase that in turn increases cyclic adenosine monophosphate (cAMP), causing the relaxation of bronchial smooth muscles.

• It is mostly used as an adjunctive agent and reserved in non-responsive patients or patients having difficulty in using inhaled agents.

• It has a narrow therapeutic index and adverse effects, like anxiety, tremors, insomnia, nausea, cardiac arrhythmia (multifocal atrial tachycardia), and seizures above the therapeutics range. Previously the recommended target range was 15-20 mg/dL. However, now it has been reduced to 8-13 mg/dL.

• It is metabolized via cytochrome P 450 system. Thus, the plasma concentration of theophylline is affected by age, cardiac status, and liver abnormalities.

Phosphodiesterase type 4 inhibitors

Roflumilast

• It helps in reducing exacerbations, improve dyspnea, and increase lung function in patients with severe COPD.

GOLD recommendations for management of COPD

GOLD recommendations for management of COPD

Stage	Degree of airway obstruction	Treatment
Stage I	Mild	Influenza vaccine (decrease risk) Short acting Beta 2 receptor agonist
Stage II	Moderate	Influenza vaccine (decrease risk) Short acting Beta 2 receptor agonist Long-acting bronchodilator Cardiopulmonary rehabilitation
Stage III	Severe	Influenza vaccine (decrease risk) Short acting Beta 2 receptor agonist Long-acting bronchodilator Cardiopulmonary rehabilitation Inhaled steroids in case of frequent exacerbation
Stage IV	Very severe or moderate with evidence of chronic respiratory failure	Influenza vaccine (decrease risk) Short acting Beta 2 receptor agonist Long term oxygen therapy Lung transplant can be considered

Symptoms for admission to emergency department

• Confusion

• Lethargy

• Labored breathing (respiratory muscle fatigue)

• Blue discoloration of skin (indicating worsening hypoxemia)

• Worsening respiratory acidosis (pH < 7.30)

External link

COPD CDC

References

Template:WikiDoc Sources